Corcept Therapeutics (CORT) 5.33 $CORT Roche Gets FDA

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 5:21 AM

Corcept Therapeutics (CORT) 5.33 $CORT

Roche Gets FDA Nod for Emergency Use of Zika Virus Test
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:41AM CDT
Roche Holdings (RHHBY) announced that the FDA has issued an Emergency Use Authorization (EUA) for its LightMix Zika rRT-PCR Test.
ANIP: 59.74 (-1.12), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45)

Novartis (NVS) Reports Positive Phase III Results on MS Drug
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:20AM CDT
Novartis AG (NVS) announced positive results from the phase III EXPAND study on its multiple sclerosis candidate BAF312.
TEVA: 50.39 (-0.17), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45), NVS: 78.77 (-0.57)

Mallinckrodt to Divest Nuclear Imaging Business for $690M
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:22AM CDT
Mallinckrodt plc (MNK) announced that it has entered into a definitive agreement to sell its Nuclear Imaging business to IBA Molecular for $690 million.
MNK: 74.54 (-0.51), MDCO: 39.17 (-0.97), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45)

Cempra's Application for Pneumonia Drug Validated in EU
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:02PM CDT
Cempra, Inc. (CEMP) announced that the EMA has validated its MAA for the oral capsule and intravenous (IV) formulations of pipeline candidate solithromycin, for the treatment of community-acquired bacterial pneumonia.
AGN: 234.54 (-2.45), CEMP: 21.94 (+0.50), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45)

J&J (JNJ) Seeks EU Approval for Darzalex's Expanded Use
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 8:10AM CDT
Johnson & Johnson's (JNJ) seeks label expansion for Darzalex in combination with standard-of-care regimens for relapsed multiple myeloma patients.
JNJ: 119.34 (-0.13), AMGN: 170.06 (-0.70), CORT: 5.33 (-0.08)

Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 7:50AM CDT
Novartis AG (NVS) entered into a license agreement with privately held Cyon Therapeutics Inc. for its anti-PCSK9 antibody, LGT-209.
XNCR: 21.13 (-0.66), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45), NVS: 78.77 (-0.57)

Gilead (GILD) Truvada Gets EU Approval for Label Expansion
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:02AM CDT
Gilead Sciences (GILD) once-daily Truvada gains EU approval for reducing the risk of sexually acquired HIV-1 infection.
GILD: 78.38 (+0.46), GERN: 2.69 (unch), CORT: 5.33 (-0.08), ANIK: 47.24 (-0.21)

Roche Launches Accu-Chek Blood Glucose Monitoring System
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:47AM CDT
The launch of new systems will help Roche (RHHBY) offset the sales decline in the diabetes care business due to pricing pressure in the U.S. and reimbursement issues
ANIP: 59.74 (-1.12), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45)

Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:52AM CDT
Supernus Pharmaceuticals, Inc. (SUPN) announced that the FDA has granted a tentative approval to the company's sNDA for a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.
ANIP: 59.74 (-1.12), SUPN: 21.38 (-0.49), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45)

What Falling Estimates & Price Mean for Merus Labs International (MSLI)
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 7:43AM CDT
One such stock that you may want to consider dropping is Merus Labs International Inc. (MSLI), which has witnessed a significant price decline in the past four weeks
MSLI: 1.01 (+0.03), CORT: 5.33 (-0.08)

Insys Therapeutics Starts Enrollment in Cannabidiol Trial
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 4:32PM CDT
Insys Therapeutics, Inc. (INSY) announced that it has enrolled the first patient in a phase II trial on its pharmaceutical cannabidiol (CBD) product candidate.
INSY: 14.27 (-0.06), GWPH: 81.75 (-0.02), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45)

Horizon (HZNP) Rayos Receives USPTO Notice of Allowance
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:22AM CDT
Horizon Pharma (HZNP) announced that it has received a notice of allowance from the U.S. Patent and Trademark Office with claims covering Rayos.
ANIP: 59.74 (-1.12), GERN: 2.69 (unch), HZNP: 18.80 (-0.21), CORT: 5.33 (-0.08)

Valeant Stock Down on Lawsuit by T. Rowe, Alters Credit Loan
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:21AM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has received the requisite lender approval for an amendment to its credit facility which is scheduled to close next week.
VRX: 29.03 (-1.22), TROW: 69.54 (-0.36), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45)

Glaxo/Pfizer ViiV Healthcare Starts HIV Drug Combo Study
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 8:59AM CDT
GlaxoSmithKline (GSK) announced that its HIV-focused company, ViiV Healthcare has initiated a phase III program to support regulatory filings for a two-drug regimen of Tivicay and Epivir for the treatment for HIV-1 infection.
PFE: 34.80 (-0.08), GSK: 43.46 (+0.10), CORT: 5.33 (-0.08)

OncoGenex Down on Poor Phase III Data on Lead Cancer Drug
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 8:57AM CDT
Shares of OncoGenex Pharmaceuticals, Inc. (OGXI) were down 41% after the company announced disappointing data from its late-stage trial, AFFINITY, on custirsen in men with metastatic castrate-resistant prostate cancer.
OGXI: 0.54 (-0.03), ANIP: 59.74 (-1.12), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45)

Endo (ENDP) Withdraws Label Expansion Filing for Opana ER
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 3:48PM CDT
Endo International (ENDP) announced that after discussions with the FDA the company has decided to withdraw its supplemental new drug application for Opana ER.
ENDP: 20.70 (-0.19), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45)

Aurinia (AUPH) Stock Falls on Poor Phase II Lupus Study Data
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 10:08AM CDT
Shares of Aurinia Pharmaceuticals Inc. (AUPH) crashed 55% after the company reported mixed results from a phase IIb study, AURA-LV, on its pipeline candidate, voclosporin.
AUPH: 1.94 (-0.01), ANIP: 59.74 (-1.12), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45)

Bristol-Myers to Reacquire Rights to Oncology Drug in Asia
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 8:26AM CDT
Bristol-Myers Squibb Company (BMY) will reacquire the rights to BMS777607 from Aslan Pharmaceuticals.
ANIP: 59.74 (-1.12), BMY: 57.39 (+0.15), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45)

Mallinckrodt (MNK) to Buy Stratatech for Undisclosed Value
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 11:24AM CDT
Mallinckrodt plc (MNK) announced that it will acquire privately held regenerative medicine company, Stratatech Corporation.
MNK: 74.54 (-0.51), MDCO: 39.17 (-0.97), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45)

Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 8:31AM CDT
Adverum (ADVM) reported a narrower-than-expected loss in the second quarter. The company also decided to discontinue the development of lead candidate.
ADVM: 3.58 (-0.16), CORT: 5.33 (-0.08), PCRX: 39.63 (-1.45), REGN: 392.55 (-2.67)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Karen Love's Retirement Marks End of an Era for TACHP

A Legacy Not Just Built, But Carved in Stone In the world of healthcare, folks like Karen Love don’t come around too often. She's stepping down from her post as President and CEO of Cook Children's Health Plan this month, and it feels like the end of a chapter for the Texas Association of Community Health Plans (TACHP). Love wasn't just an executive; she was a mover and...

Ace Hardware Ups the Stakes with Rewards Days Event

Ace Hardware: Doubling Down with Rewards Ace Hardware's rolling out the red carpet for its loyal customers. Imagine this: exclusive deals on trusted brands and double points on purchases—an incentive any savvy shopper would jump at. From October 6 to 7, those in the Ace Rewards circle have the chance to nab some hefty savings and perks, a move that's more than just a...

Gateway Unveils All-In-One Award Travel Platform

Transforming Loyalty with point.me's Gateway Here's the deal: the loyalty program game just changed. Point.me rolled out this slick beast called Gateway, and it's weaving award travel booking right into your everyday banking apps. That's right, ditch those clunky third-party sites, because now you can browse, compare, transfer, and book your award travel directly from...

Varda Space's Dual Launch Signals Orbital Ambitions

It's not every day you see two commercial rockets heading to orbit on the same ride, but that's precisely what Varda Space Industries just pulled off. With the W-8 and W-9 vehicles blasting off together, Varda is positioning itself for a leap in orbital operations. They've hitched a ride aboard SpaceX's Transporter-18 mission, and this is more than just a double...

Concrete Pipe: Foundation of Modern Infrastructure

Reinforced Concrete Pipes Hold Their Ground You know, it might not be the flashiest part of our infrastructure toolkit, but concrete pipe plays a mighty big role behind the scenes. Even in this age of shiny new tech and constantly evolving materials, the classic concrete pipe still packs a punch—especially when you demand something that'll last. Enter Stephanie Ward, a...

Fresh Leadership at Master Group: Langelier Steps In

Changing of the Guard: A Calculated Move It's not every day you see a company make a move as calculated and thoughtful as the one the Master Group just pulled. Rémy Langelier is set to transition into the shoes of CEO by early 2027, fresh off the heels of Louis St-Laurent. This isn't just any executive shuffle, folks—it's a strategic baton pass spawning an investment...

Cannatrol and Veterans Nonprofit Unite for Healing

Veterans Find a New Ally in Cannabis Tech When two distinct worlds collide for a cause, it can create waves of change much bigger than simple collaboration. That's exactly what's happening with Cannatrol and Operation Green Healing, a partnership that could redefine support for our veterans. Cannatrol, renowned for its groundbreaking post-harvest cannabis technology, has...

Texas A&M-San Antonio's Research Expansion Momentum

Texas A&M-San Antonio's Rising Research Ambitions A rainy day in San Antonio and Texas A&M University-San Antonio seems to have set the stage for more than just another semester of record enrollment. They’ve just rolled in with an exhilarating $8 million in external grants this fiscal year, more than doubling last year’s haul of $3.6 million, in a bid to push their...

Neutonic Sets Sights on U.S. with Walmart Expansion

Neutonic Embarks on Major Expansion with Walmart Well, here we go. Neutonic is stepping up to the big leagues by planting its flag in nearly 1,000 Walmart stores across the U.S. This move lands them right in the thrumming heart of Walmart's new Mood & Mind beverage set. It's about time this brand brings its functional beverages to American shoppers already drained by...

Haystack MRD Shines in Colorectal Cancer Trials

A New Dawn in Cancer Detection Just when you think you've seen it all in cancer diagnostics, Haystack MRD® pops up like a fresh tulip in spring. And listen, this ain't just fluff—the results from the DYNAMIC trials are a pretty compelling love letter to the power of liquid biopsy. With 100% specificity and sensitivity hitting a whopping 83.3% over five years, it’s...